MX389198B - Inhibidores de proteína-cinasas relacionados a ataxia-telengiectasia y rad3 (atr). - Google Patents
Inhibidores de proteína-cinasas relacionados a ataxia-telengiectasia y rad3 (atr).Info
- Publication number
- MX389198B MX389198B MX2017004515A MX2017004515A MX389198B MX 389198 B MX389198 B MX 389198B MX 2017004515 A MX2017004515 A MX 2017004515A MX 2017004515 A MX2017004515 A MX 2017004515A MX 389198 B MX389198 B MX 389198B
- Authority
- MX
- Mexico
- Prior art keywords
- rad3
- atr
- protein kinase
- kinase inhibitors
- ataxia telengiectasia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Biomedical Technology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063176P | 2014-10-13 | 2014-10-13 | |
| US201562104274P | 2015-01-16 | 2015-01-16 | |
| PCT/US2015/055317 WO2016061097A1 (en) | 2014-10-13 | 2015-10-13 | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004515A MX2017004515A (es) | 2017-10-31 |
| MX389198B true MX389198B (es) | 2025-03-20 |
Family
ID=55654998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004515A MX389198B (es) | 2014-10-13 | 2015-10-13 | Inhibidores de proteína-cinasas relacionados a ataxia-telengiectasia y rad3 (atr). |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9663535B2 (en:Method) |
| EP (1) | EP3207031B1 (en:Method) |
| JP (1) | JP6678679B2 (en:Method) |
| KR (1) | KR102569226B1 (en:Method) |
| CN (1) | CN107108527B (en:Method) |
| AU (1) | AU2015333738B2 (en:Method) |
| BR (1) | BR112017007708B8 (en:Method) |
| CA (1) | CA2963973C (en:Method) |
| ES (1) | ES2879441T3 (en:Method) |
| IL (1) | IL251595B (en:Method) |
| MX (1) | MX389198B (en:Method) |
| WO (1) | WO2016061097A1 (en:Method) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963973C (en) | 2014-10-13 | 2023-01-10 | Atrin Pharmaceuticals LLC | Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
| US10301324B2 (en) | 2016-04-12 | 2019-05-28 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| ES2974334T3 (es) | 2017-07-13 | 2024-06-26 | Univ Texas | Inhibidores heterocíclicos de ATR cinasa |
| WO2019036641A1 (en) | 2017-08-17 | 2019-02-21 | Board Of Regents, The University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| WO2019055657A1 (en) * | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | BAF COMPLEX MODULATION COMPOUNDS AND METHODS OF USE |
| WO2019178590A1 (en) | 2018-03-16 | 2019-09-19 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of atr kinase |
| CN110357905B (zh) * | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
| US11980613B2 (en) | 2018-07-12 | 2024-05-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for reversing HIV latency using BAF complex modulating compounds |
| CN110950890B (zh) * | 2018-09-27 | 2022-07-01 | 北京赛林泰医药技术有限公司 | 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂 |
| KR20210097124A (ko) | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| JP7774621B2 (ja) | 2020-10-16 | 2025-11-21 | シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド | 三複素環誘導体、その医薬組成物及び使用 |
| AU2023254110A1 (en) * | 2022-04-14 | 2024-10-24 | Aprea Therapeutics, Inc. | Atr inhibitors |
| JP2025522390A (ja) | 2022-06-15 | 2025-07-15 | アストラゼネカ・アクチエボラーグ | 癌を処置するための併用療法 |
| WO2025181153A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA13151A (en) * | 2003-02-26 | 2006-12-13 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors. |
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| MX2011006503A (es) | 2008-12-19 | 2011-09-06 | Vertex Pharma | Derivados de pirazina utiles como inhibidores de la cinasa de atr. |
| EP2569287B1 (en) * | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012125603A1 (en) * | 2011-03-16 | 2012-09-20 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
| DK2822953T5 (en) * | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| CN104284891B (zh) * | 2012-03-17 | 2018-04-17 | 波利弗尔股份公司 | 构象受限的全合成大环化合物 |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| CA2963973C (en) | 2014-10-13 | 2023-01-10 | Atrin Pharmaceuticals LLC | Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
-
2015
- 2015-10-13 CA CA2963973A patent/CA2963973C/en active Active
- 2015-10-13 ES ES15850553T patent/ES2879441T3/es active Active
- 2015-10-13 JP JP2017538930A patent/JP6678679B2/ja active Active
- 2015-10-13 BR BR112017007708A patent/BR112017007708B8/pt active Search and Examination
- 2015-10-13 US US14/881,680 patent/US9663535B2/en active Active
- 2015-10-13 MX MX2017004515A patent/MX389198B/es unknown
- 2015-10-13 EP EP15850553.7A patent/EP3207031B1/en active Active
- 2015-10-13 WO PCT/US2015/055317 patent/WO2016061097A1/en not_active Ceased
- 2015-10-13 AU AU2015333738A patent/AU2015333738B2/en active Active
- 2015-10-13 KR KR1020177012838A patent/KR102569226B1/ko active Active
- 2015-10-13 CN CN201580067182.7A patent/CN107108527B/zh active Active
-
2017
- 2017-04-05 IL IL251595A patent/IL251595B/en unknown
- 2017-04-27 US US15/498,631 patent/US9981989B2/en active Active
-
2018
- 2018-04-12 US US15/951,302 patent/US10196405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180230168A1 (en) | 2018-08-16 |
| KR20170082532A (ko) | 2017-07-14 |
| ES2879441T3 (es) | 2021-11-22 |
| WO2016061097A1 (en) | 2016-04-21 |
| BR112017007708B8 (pt) | 2023-10-24 |
| US20170226130A1 (en) | 2017-08-10 |
| MX2017004515A (es) | 2017-10-31 |
| CA2963973C (en) | 2023-01-10 |
| EP3207031A4 (en) | 2018-02-14 |
| BR112017007708A2 (pt) | 2017-12-19 |
| JP6678679B2 (ja) | 2020-04-08 |
| KR102569226B1 (ko) | 2023-08-22 |
| US10196405B2 (en) | 2019-02-05 |
| CN107108527B (zh) | 2022-08-02 |
| CA2963973A1 (en) | 2016-04-21 |
| BR112017007708B1 (pt) | 2023-07-25 |
| EP3207031B1 (en) | 2021-04-14 |
| US9981989B2 (en) | 2018-05-29 |
| US9663535B2 (en) | 2017-05-30 |
| EP3207031A1 (en) | 2017-08-23 |
| JP2017531041A (ja) | 2017-10-19 |
| AU2015333738B2 (en) | 2020-03-26 |
| IL251595B (en) | 2022-04-01 |
| IL251595A0 (en) | 2017-06-29 |
| CN107108527A (zh) | 2017-08-29 |
| BR112017007708A8 (en:Method) | 2017-12-19 |
| US20160102104A1 (en) | 2016-04-14 |
| AU2015333738A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389198B (es) | Inhibidores de proteína-cinasas relacionados a ataxia-telengiectasia y rad3 (atr). | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| CY1123801T1 (el) | Παραγωγα αρωματικου σουλφοναμιδιου | |
| CO2019005165A2 (es) | Compuesto de piridona como inhibidor de c-met | |
| CY1120703T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
| DOP2015000251A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| MX390347B (es) | Compuestos de aminotiazol como inhibidores de c-kit. | |
| BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| AR101995A1 (es) | COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6 | |
| AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| MX2018012085A (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| MX2017002328A (es) | Analogos de dioxolano de uridina para el tratamiento del cancer. | |
| MX2017003999A (es) | Derivados de acido boronico. | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| MX387483B (es) | Preparación farmacéutica. | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| BR112016026787A8 (pt) | Derivados de quinzaolina-4(3h)-ona antibacterianos | |
| ECSP16096831A (es) | Derivados de naftiridinadiona |